Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 6/20 | 0.53 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.46 |
| ▸ | CCR5 | P51681 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | CCR3 | P51677 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3282383 | 0.89 | GPR119 (0.59) | GPR119HRH3CHEK2HRH1CCR3 | |
| SCHEMBL5406049 | 0.86 | GPR119 (0.48) | GPR119HRH3CHEK2CCR5HRH1 | |
| SCHEMBL5462103 | 0.84 | GPR119 (0.58) | GPR119HRH3CHEK2HRH1CCR3 | |
| SCHEMBL5194646 | 0.84 | CCR3 (0.47) | GPR119HRH3CCR5HRH1CCR3 | |
| SCHEMBL5414237 | 0.83 | GPR119 (0.52) | GPR119HRH3CHEK2HRH1CCR3 | |
| SCHEMBL4720822 | 0.83 | HRH1 (0.62) | GPR119HRH3HRH1CCR3 | |
| SCHEMBL20570284 | 0.82 | GPR119 (0.57) | GPR119HRH3CHEK2 | |
| SCHEMBL5469410 | 0.81 | USP30 (0.47) | GPR119CHEK2HRH1CCR3 | |
| SCHEMBL16622456 | 0.81 | GPR119 (0.50) | GPR119CHEK2 | |
| SCHEMBL4140781 | 0.80 | HRH1 (0.64) | HRH1CCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8049012-B2 | 3-aza-spiro[5.5]undecane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | NEUROSEARCH A/S (DK) | 2011-11-01 | — | — | US | disclosed |
| EP-1899303-B1 | NOVEL 3-AZA-SPIRO[5.5]UNDECANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH AS (DK) | 2010-09-15 | — | — | EP | disclosed |
| US-20090227613-A1 | Novel 3-Aza-Spiro[5.5]Undecane Derivatives and Their Use As Monoamine Neurotransmitter Re-Uptake Inhibitors | NEURO SEARCH A/S (DK) | 2009-09-10 | — | — | US | disclosed |
| EP-1899303-A1 | NOVEL 3-AZA-SPIRO[5.5]UNDECANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NeuroSearch A/S (DK) | 2008-03-19 | — | — | EP | disclosed |
| WO-2007000465-A1 | NOVEL 3-AZA-SPIRO[5.5]UNDECANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227613-A1 | Novel 3-Aza-Spiro[5.5]Undecane Derivatives and Their Use As Monoamine Neurotransmitter Re-Uptake Inhibitors | SLC18A2, SLC6A2, SLC6A3 | FFAR4 1027/4885GPR119 187/4885HRH3 913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.